PEH's Portfolio Company Enanta announces U.S. FDA Approval for AbbVie's VIEKIRA PAK(TM)
Zug, December 22, 2014
Enanta Pharmaceutical Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs primarily in the infectious disease field is Private Equity Holding AG's largest direct investment. Enanta has announced that the U.S. Food and Drug Administration has approved AbbVie's VIEKIRA PAK(TM) for the Treatment of Chronic Genotype 1 Hepatitis C Virus.
The VIEKIRA PAK regimen contains Enanta's lead protease inhibitor paritaprevir (formerly ABT-450) and cured 95-100 percent of Hepatitis C patients, with less than two percent of patients experiencing virological failure in Phase 3 clinical trials. For more information, please refer to http://ir.enanta.com/phoenix.zhtml?c=147990&p=irol-newsArticle&ID=2001257.
PEH had invested in Enanta in 1999 as part of the original shareholder syndicate and backed the current management team through a strategic reorientation of the business in 2002. PEH participated in several financing rounds thereafter and the initial public offering in 2013 - all of which has created very significant value for PEH's shareholders to date.
Private Equity Holding AG (SIX: PEHN) offers investors the opportunity to invest, within a simple legal and tax optimized structure, in a broadly diversified and professionally managed private equity portfolio.
For further information, please contact:
Emanuel Eftimiu, Investor Relations, firstname.lastname@example.org, phone +41 41 726 79 80, http://www.peh.ch